Transseptal catheterization is frequently performed to
|
|
- Isaac Rose
- 5 years ago
- Views:
Transcription
1 The Incidence and Long-Term Clinical Outcome of Iatrogenic Atrial Septal Defects Secondary to Transseptal Catheterization With a 12F Transseptal Sheath Sheldon M. Singh, MD; Pamela S. Douglas, MD, MACC, FAHA; Vivek Y. Reddy, MD, FACC Background Studies assessing the presence of a residual iatrogenic atrial septal defect (iasd) after transseptal catheterization with 8F transseptal sheaths have suggested that the majority of these iasds close within 6 months. However, these studies have been limited by small patient numbers and short follow-up. Additionally, there are a number of novel catheter procedures in interventional cardiology and electrophysiology that use larger transseptal sheaths. The objective of this study was to assess the incidence of and complications associated with iasds in a large cohort of patients undergoing transseptal catheterization with a 12F transseptal sheath. Methods and Results Patients (n 253) without a preexisting interatrial shunt undergoing WATCHMAN implantation as part of the PROTECT AF study were included in this current study. Patients underwent transesophageal echocardiography with echo-contrast immediately after the procedure and at 45 days and 6 months and 12 months. Eighty-seven percent of patients had an iasd immediately after the procedure, the majority of which sealed by 6 months (incidence of iasd, 34% at 45 days, 11% at 6 months, 7% at 12 months). Whereas the majority of iasds were 3 mm in diameter immediately after the procedure, the minority of iasd were 3 mm during the follow-up period. Additionally, interatrial shunting was predominantly left-to-right when an iasd was present. There was no significant difference in the rate of stroke and/or systemic embolism during the follow-up period in patients with or without iasd. Conclusions Transseptal catheterization procedures with a large-diameter transseptal sheath have a high spontaneous closure rate of iasds that is not associated with an increased rate of stroke/systemic embolization during long-term follow-up. (Circ Arrhythm Electrophysiol. 2011;4: ) Key Words: atrial septal defect transseptal catheterization atrial fibrillation Transseptal catheterization is frequently performed to access the left heart during percutaneous cardiac procedures. The increasing complexity of these procedures has resulted in the use of larger-diameter transseptal sheaths. For example, a 12F transseptal sheath (with a 14F outer diameter) is used during implantation of the WATCHMAN left atrial appendage (LAA) closure device, 1 pulmonary vein isolation procedures with the Endoscopic Laser balloon ablation catheter system, 2 and use of the Hansen robotic navigation system. 3 The use of such large-diameter sheaths has raised concerns of persistent iatrogenic atrial septal defects (iasds), which may be associated with right-to-left cardiac shunting and paradoxical embolic events. Current studies assessing the incidence of iasds after transseptal catheterization suggest that the majority of iasds close by 6 months. 4 6 However, these studies are limited by small sample sizes and short follow-up periods, which may prevent an accurate estimation of the incidence and complications associated with iasd. In addition, these data were largely obtained after transseptal puncture using 8F sheaths. Clinical Perspective on p 171 The PROTECT AF study was a prospective, multicenter, randomized, controlled trial that evaluated the safety and efficacy of percutaneous LAA closure versus warfarin therapy in patients with nonvalvular atrial fibrillation. 1 Patients randomly assigned to the WATCHMAN device implantation subsequently underwent serial transesophageal echocardiography (TEE) imaging, thereby permitting an assessment of the natural history of iasds secondary to the use of a large-diameter transseptal sheath. We report on the incidence Received July 29, 2010; accepted December 20, From the Cardiac Arrhythmia Service (S.M.S., V.Y.R.), Mount Sinai School of Medicine, New York, NY; and Duke Clinical Research Institute (P.S.D.), Durham, NC. Correspondence to Vivek Y. Reddy, MD, Mount Sinai School of Medicine, Zena and Michael A. Weiner Cardiovascular Institute, One Gustave L. Levy Place, Box 1030, New York, NY vivek.reddy@mountsinai.org 2011 American Heart Association, Inc. Circ Arrhythm Electrophysiol is available at DOI: /CIRCEP
2 Singh et al iasd After Transseptal Puncture With a 12F Sheath 167 and clinical outcomes associated with iasds in a large subgroup of patients without a preexisting interatrial shunt who underwent transseptal catheterization with a single 12F transseptal sheath. Methods The PROTECT AF trial was a prospective, randomized, controlled trial evaluating the efficacy of LAA closure with the WATCHMAN device compared with warfarin therapy in patients age 18 years and older with a history of paroxysmal, persistent, or permanent nonvalvular atrial fibrillation and CHADS 2 score of 1 or more. The details and results of the study have been previously published. 1 Four hundred sixty-three patients were assigned to receive LAA closure during the randomization process, 14 of whom device implantation was not attempted and 41 of whom device implantation was attempted but not possible. Additionally, the device was successfully implanted in 77 non randomly assigned roll-in patients, for a total of 485 patients who underwent device implantation in this trial. Exclusion Criteria Patients with a patent foramen ovale, atrial septal aneurysm (excursion and/or length 15 mm), and/or large shunt (within 3 beats and accompanied by a substantial passage of bubbles) were excluded from the PROTECT AF study. Additionally, patients without a baseline echo result, those with any interatrial shunt before WATCHMAN device implantation, or those with missing echo results available at a follow-up visits were excluded from the current subgroup of patients reported in the present study. TEE Imaging All patients underwent TEE imaging at baseline, intraoperatively, and at 45 days and 6 and 12 months, using commercially available TEE imaging equipment with at least a 5.0-MHz multiplane transducer. Multiple images of the interatrial septum were obtained both with and without color Doppler. In all patients, agitated saline was injected to assess for the presence of an interatrial shunt. The size and direction of the detected interatrial shunt was documented. If present, the length and excursion of an interatrial septal aneurysm were noted. Shunt fractions (Qp/Qs) were not routinely determined. All images were obtained for at least 5 cardiac cycles in each 2D view, or 10 cardiac cycles if the patient was not in sinus rhythm. Images and measurements were reviewed by an independent Core Echocardiography Laboratory (COResearch, Durham, NC). Transseptal Puncture Transseptal puncture was frequently performed with a long 8.5F SL-1 type vascular sheath that was subsequently exchanged over a guide wire for the 12F transseptal sheath (with a 14F outer diameter) used for delivering the WATCHMAN device (Figure 1). Transseptal punctures were generally performed with TEE guidance. Typically, transseptal punctures were placed slightly anterior to the typical puncture site used during atrial fibrillation ablation procedures. Follow-Up After successful device implantation, all patients remained on warfarin for a minimum of 45 days to permit device endothelialization. Warfarin therapy was discontinued at 45 days if TEE imaging demonstrated complete exclusion of the LAA or residual peridevice flow with jet width 5 mm, at which point daily clopidogrel (75 mg) and aspirin (81 to 325 mg) was administered an additional 4.5 months, followed by daily aspirin indefinitely. Figure 1. The 14F outer diameter WATCHMAN transseptal sheath. All adverse events (including neurological and other embolic events) were reviewed and adjudicated by an independent clinical events committee. Statistical Analysis Continuous variables are reported as mean SD. Categorical variables are reported in frequencies (percentages). Significant differences between patients with and without an iasd at 12 months were determined with univariate analysis of the 2 groups using the Student t test for continuous and the 2 test for categorical variables. The relationship between the occurrence of ischemic strokes/systemic embolism and the presence of an iasd was assessed using a Cox proportional hazards model with adjustment made for CHADS 2 score. All statistical analysis was performed with SAS software version 9.2 (SAS Institute Inc, Cary, NC). Probability values 0.05 were considered statistically significant. Ethics All patients provided written informed consent before participating in the study. The study was reviewed by the US Food and Drug Administration and was approved by each participating center s institutional review board. The study sponsor had no role in the interpretation of these data or writing of the final report. Results Four hundred eighty-five patients underwent implantation of the WATCHMAN device in the PROTECT AF study. Of these, 449 patients had baseline atrial shunt status available. We report on the cohort of 253 patients without a prior interatrial shunt who subsequently underwent implantation of the WATCHMAN device using the single 12F transseptal access sheath and who had complete follow-up for atrial shunt status. Excluded from this report are those without evidence of an absence of interatrial shunt before WATCHMAN device implantation (n 76 or those missing echo results at one or more follow-up visits (n 120). The average follow-up per patient in this cohort was 29 months (range, 11 to 55 months). Frequency of iasds During the Follow-Up Period TEE imaging was performed and reviewed by the core laboratory for intervals after the procedure and at 45 days, 6 months, and 12 months in 211 (83%), 234 (92%), 218 (86%) and 208 (82%) patients, respectively. Table 1
3 168 Circ Arrhythm Electrophysiol April 2011 Table 1. Proportion of Patients, Size, and Direction of Interatrial Shunt Immediately, 45 days, and 6 and 12 Months After WATCHMAN Implantation Patients With Shunt Size, % Direction of Shunt Shunt, n (%) 3 mm 3 mm Unknown Left-to-Right Bidirectional Right-to-Left Unknown Postprocedure 183 (87%) 69 (38%) 111 (61%) 3 (2%) 164 (90%) 9 (5%) 7 (4%) 3 (2%) 45 Days 80 (34%) 56 (70%) 22 (28%) 2 (3%) 65 (81%) 8 (10%) 5 (6%) 2 (3%) 6 Months 25 (11%) 17 (68%) 6 (24%) 2 (8%) 22 (88%) 1 (4%) 2 (8%) 0 (0%) 12 Months 14 (7%) 7 (50%) 4 (29%) 3 (21%) 7 (50%) 3 (21%) 4 (29%) 0 (0%) summarizes the proportion of patients with iasds and the size and direction of iasd shunting documented on TEE imaging immediately after the procedure and at 45 days and 6 and 12 months. An iasd was detected in 87% of patients immediately after the procedure, with this value decreasing to 34% at 45 days, 11% at 6 months, and 7% at 1 year. Although the majority of patients with iasds immediately after the procedure had an iasd 3 mm (Figure 2), only a minority of patients had an iasd 3 mm from 45 days onward. Left-to-right shunting was predominant when an iasd shunt was noted (Figure 3). Factors Associated With Postprocedural iasd Table 2 summarizes demographic, anatomic, and procedural characteristics for patients with and without an iasd noted immediately after the procedure. There was no association between factors such as age, CHADS 2 score, LA size, procedure time, and the presence of a postprocedural iasd. Of note, the LA pressure measured on the day of WATCHMAN device implantation was elevated and significantly higher in patients with an iasd compared with patients without an iasd ( mm Hg versus mm Hg, P 0.011). Although there was no significant difference in the proportion of patients with mitral regurgitation, the average degree of mitral regurgitation was not available for each group. Embolic Events During the Follow-Up Period Nine ischemic strokes/systemic embolism occurred during the follow-up period in this cohort: 5 occurred in patients with an immediate postprocedure iasd and 4 in patients without a postprocedure iasd. Six of the ischemic strokes/ systemic embolism occurred after 1 year of follow-up; 1 occurred in a patient with an iasd present on the 12-month TEE and 5 in patients without an iasd present on the 12-month TEE. Table 3 summarizes the event rate per patient-years of follow-up and hazard ratios with confidence intervals (unadjusted and adjusted for CHADS 2 score) for patients with and without an iasd detected immediately after the procedure, at 12 months, and the event rate per patient-years of follow-up for events occurring after 12 months. There was no significant increase in the risk of stroke/systemic embolism in patients with an iasd after the procedure or at 12 months. Discussion In experienced hands, transseptal catheterization can be performed with minimal complications 7 ; however, acute procedure-related iasd are inevitable. This study assessed the long-term incidence of iasds in a large cohort of patients undergoing transseptal catheterization with a 12F inner/14f outer diameter transseptal sheath. The main findings of this study are (1) the incidence of iasd is high (87%) immediately after transseptal catheterization, (2) the majority of iasds resolve within 45 days of the procedure, with less than 10% of the patients having a residual iasd at 12 months, (3) right-to-left shunting is rare when an iasd is present, and (4) patients with an iasd did not have a significant increase in the risk of stroke/systemic embolism compared with patients without an iasd. Figure 2. Atrial septal defect 3 mm in size noted immediately after WATCHMAN implantation. Color Doppler flow across the atrial septum immediately after WATCHMAN implantation demonstrating a 3.7-mm iasd with a left-to-right shunt. LA indicates left atrium; RA, right atrium. Figure 3. Left-to-right interatrial shunting in a patient 6 months after WATCHMAN implantation. Color Doppler flow across the atrial septum 6 months after WATCHMAN implantation demonstrating a small ( 3 mm) iasd with a left-to-right shunt. LA indicates left atrium; RA, right atrium.
4 Singh et al iasd After Transseptal Puncture With a 12F Sheath 169 Table 2. Demographic, Clinical, and Procedural Characteristics for Patients With and Without a Postprocedural Interatrial Shunt Postprocedure Shunt Present Postprocedure Shunt Absent P Value Age, y, mean SD Female sex, n (%) 53/183 (29.0%) 21/70 (30.0%) Hypertension, n (%) 170/183 (92.9%) 60/70 (85.7%) Diabetes, n (%) 36/183 (19.7%) 21/70 (30.0%) Prior TIA/stroke, n (%) 33/183 (18.0%) 12/70 (17.1%) CHADS 2 score, mean SD Paroxysmal atrial fibrillation, 79/183 (43.2%) 26/70 (37.1%) n (%) On warfarin at 12 mo, n (%) 13/183 (7.1%) 6/70 (8.6%) LA width, cm, mean SD LA length, cm, mean SD MV regurgitation, (n (%)) 162/183 (88.5%) 61/70 (87.1%) LA pressure, mm Hg, mean SD Procedure time, min, mean SD TIA indicates transient ischemic attack; MV, mitral valve. Evolving percutaneous therapies for various cardiac conditions are being developed, many of which require use of large-diameter transseptal sheaths. For example, novel balloon ablation strategies for atrial fibrillation with the endoscopic laser balloon 2 or cryoballoon catheters 8 require access to the LA with either a 14F or 15F outer diameter transseptal sheath, respectively. Likewise, various LAA closure devices use sheaths with outer diameters ranging from 12F to 15F. 1,9 Thus, knowledge of the natural history of iasds associated with large transseptal sheaths is vital, given the potential widespread clinical applicability of the above mentioned technology in patients with atrial fibrillation. As expected, the majority of patients in this series had an iasd detected immediately after the procedure. The only clinical factor that was significantly different between the group with and that without a postprocedural iasd was Table 3. the LA pressure at the time of device implantation. Not only was the LA pressure difference significantly higher in patients with an iasd, but this value was elevated above the upper limits of normal for LA pressure. Although not confirmed in a prior study, 10 these data suggest that LA pressure influences the patency and/or detection of an iasd on TEE imaging. Additionally, because most patients with atrial fibrillation have near normal right and left atrial pressures in the absence of significant valvular heart disease, the predominance of left-to-right shunting in patients with an iasd is suggestive of ongoing elevations in LA pressure. Although the clinical consequences (that is, paradoxical embolism) of right-to-left shunting in patients with an iasd is frequently of concern, one cannot ignore the possible detrimental consequences of left-toright cardiac shunting (right heart volume overload and pulmonary hypertension). Adverse consequences of leftto-right intracardiac shunting was not noted in this series of patients; this probably is related to the small size of the iasd and accompanying small shunt fraction, which is likely to have minimal clinical sequelae. In this study, there was no clinical evidence of right heart volume overload and pulmonary hypertension. Although the findings of our work suggest that the use of larger-diameter transseptal sheaths may not be associated with a significant increase in the incidence and complications related to the presence of an iasd, it must be recognized that the these findings are limited to a specific population of patients undergoing transseptal catheterization with placement of a 14F outer diameter sheath. It is possible that the incidence and complications of iasd may be higher when larger diameter transseptal sheaths are used. For example, Rilling et al 10 reported on 40 patients undergoing a single-puncture, double-transseptal procedure with 14F and 8.5F outer diameter sheaths. The prevalence of iasd was 21.1% at 6 months. Hammerstingl et al 5 reported on 27 patients who underwent a single transseptal puncture followed by the combined placement of both an 8F transseptal sheath and an adjacent catheter though the single puncture site. Approximately 30% of patients were noted to have a persistent iasd at 9-month follow-up. Thus, larger-diameter sheaths might result in a Stroke/Systemic Embolism During the Follow-Up Period in Patients With and Without iasd Events During the Follow-Up Period/Patient-Years of Follow Up (Rate Per 100 Patient-Years) Risk Factor/Time Point Shunt Present Shunt Absent Hazard Ratio (95% CI) P Value Postprocedure 5/438.7 (1.1) 4/155.7 (2.6) 0.45 ( ) 0.24 Postprocedure, adjusted for CHADS 2 score 0.46 ( ) Months 1/31.6 (3.2) 8/562.8 (1.4) 2.35 ( ) Months adjusted for CHADS 2 score 1.16 ( ) Months, only stroke/systemic embolism after 1/30.1 (3.3) 5/549.8 (0.9) 4.08 ( ) mo assessed 12 Months, only stroke/systemic embolism after 2.14 ( ) mo assessed adjusted for CHADS 2 score
5 170 Circ Arrhythm Electrophysiol April 2011 higher rate of iasd. Further work examining the incidence and clinical consequence of iasds with very largediameter transseptal sheaths such as the 21F sheath required for the percutaneous left ventricular assist device 11 and the 24F sheath required for the percutaneous mitral valve clip 12 is prudent. Limitations First, the study was a retrospective post hoc analysis of data derived from a randomized clinical trial. As such, immeasurable differences between the groups may be present; however, no large differences in the most important demographic, clinical, and procedural characteristics were noted (see Table 2). Second, the sensitivity of TEE for the detection of an iasd is not 100%. 13 However, this is a commonly used tool in clinical practice to detect iasd. Moreover, the concomitant use of saline contrast and, on occasion, color Doppler, allows for optimization of the sensitivity of this test for detection of clinically important iasd. Third, all patients in this study were on warfarin therapy for at least 45 days, followed by aspirin and clopidogrel therapy for 4.5 months thereafter. It is possible that the use of anticoagulant and antiplatelet agents may have reduced the risk of paradoxical embolization associated with an iasd. However, this is unlikely to have invalidated our primary findings as the risk or stroke/systemic embolism was also low during the follow-up period when anticoagulation was withdrawn. In addition, current clinical practice warrants that most patients undergoing left atrial procedures such as atrial fibrillation ablation are maintained on anticoagulant and/or antiplatelet agents for at least 3 to 6 months after the procedure. Fourth, it is possible that the higher than usual left atrial pressures ( mm Hg) encountered in this patient population minimized the incidence of right-to-left shunting noted on TEE imaging and hence the rate of paradoxical embolism. While possible, the clinical characteristics of patients in this cohort are typical of patients undergoing other left heart procedures with transseptal catheterization, and thus our results remain clinically relevant. Fifth, the overall clinical event rate was small, and clinical events simply reported as stroke or systemic embolism and not adjudicated as to whether they may be related to a paradoxical embolism. Thus, it is likely that the clinical event rate specifically related to paradoxical embolism secondary to the presence of an iasd is even lower. Sixth, other complications associated with iasds such as migraines were not reported. Given the low incidence of migraines reported in other series patients undergoing transseptal catheterization, 14 our primary clinical findings stand on their own. The strength of our work lies in the sample size, which is the largest to date reporting on the incidence of iasd in patients undergoing transseptal catheterization, the long follow-up period, systematic imaging protocol, and reporting of clinical events. In summary, patients undergoing transseptal catheterization procedures with a large-diameter transseptal sheath have a high spontaneous closure rate of iasds and no increased rate of stroke/systemic embolization during long-term follow-up. The consistency of these findings with previously reported work speaks to the safety of iasds associated with routine transseptal catheterization with 12F and smaller diameter sheaths. Systematic imaging to assess for iasd in patients who have undergone routine transseptal catheterization is not necessary, nor is the institution of specific therapy if this incidental finding is discovered. Sources of Funding Funding for the PROTECT AF study was provided by Atritech (Plymouth, MN). Disclosures Drs Reddy and Douglas have received clinical grant support from Atritech. References 1. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P, for the PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a non-inferiority randomized trial. Lancet. 2009;374: Reddy VY, Neuzil P, Themistoclakis S, Danik SB, Bonso A, Rossillo A, Raviele A, Schweikert R, Ernst S, Kuck KH, Natale A. Visually guided balloon catheter ablation of atrial fibrillation: experimental feasibility and first-in-human multicenter clinical outcome. Circulation. 2009;120: Schmidt B, Tilz R, Kars Neven K, Chun KR, Fuernkranz A, Ouyang F. Remote robotic navigation and electroanatomical mapping for ablation of atrial fibrillation: considerations for navigation and impact on procedural outcome. Circ Arrhythm Electrophysiol. 2009;2: Obel O, Mansour M, Picard M, Ruskin J, Keane D. Persistence of septal defects after transseptal puncture for pulmonary vein isolation procedures. Pacing Clin Electrophysiol. 2004;27: Hammerstingl C, Likfett L, Jeong KM, Troatz C, Wedekind JA, Tiemann K, Luderitz B, Lewalter T. Persistence of iatrogenic atrial septal defect after pulmonary vein isolation: an underestimated risk? Am Heart J. 2006;152:362.e1 362.e5. 6. Rilling A, Meyerfeldt U, Birkemeyer R, Treusch F, Kunze M, Jung W. Persistent atrial septal defect after pulmonary vein isolation: incidence and clinical implications. J Interv Card Electrophysiol. 2008;22: De Ponti R, Cappato R, Curnis A, Della Bella P, Padeletti L, Raviele A, Santini M, Salerno-Uriarte JA. Trans-septal catheterization in the electrophysiology laboratory: data from a multicenter survey spanning 12 years. J Am Coll Cardiol. 2006;47: Chierchia GB, de Asmundis C, Muller-Burri SA, Sarkozy A, Capulzini L, Paperella G, Chierchia S, Roos M, Brugada P. Early recovery of pulmonary vein conduction after cryoballoon ablation for paroxysmal atrial fibrillation: a prospective study. Europace. 2008; 11: AGA Medical Corporation. Amplatzer Cardiac Plug: Instructions for use. Available at: docs/ _amplatzer_cardiacplug_instructions_for_use_ OUS_Only_01_11_10.pdf. 10. Rilling A, Meyerfeldt U, Kunze M, Birkemeyer R, Miljak T, Jackle S, Hajredini B, Treusch F, Jung W. Persistent iatrogenic atrial septal defect after a single puncture, double transseptal approach for pulmonary vein isolation using a remote robotic navigation system: results from a prospective study. Europace. 2010;12: Sur JP, Pagani FD, Moscucci M. Percutaneous closure of an iatrogenic atrial septal defect. Catheter Cardiovasc Interv. 2009;73:
6 Singh et al iasd After Transseptal Puncture With a 12F Sheath Ussia GP, Barbanti M, Tamburino C. Feasibility of percutaneous transcatheter mitral valve repair with the MitraClip system using conscious sedation. Catheter Cardiovasc Interv. 2010;75: Kronzon I, Ruiz CE. Diagnosing patent foramen ovale: too much or too little. J Am Coll Cardiol Cardiovasc Imaging. 2010;3: Chilukuri K, Sinha S, Berger R, Marine JE, Cheng A, Nazarian S, Scherr D, Spragg D, Calkins H, Henrikson CA. Association of transseptal punctures with isolated migraine aura in patients undergoing catheter ablation of cardiac arrhythmias. J Cardiovasc Electrophysiol. 2009;20: CLINICAL PERSPECTIVE The increasing complexity of procedures involving the left atrium has resulted in the use of larger-diameter transseptal sheaths, which raises concern for persistent iatrogenic atrial septal defects (iasds) that may be associated with paradoxical embolic events. This study assessed the incidence of and clinical consequences of persistent iasds related to transseptal catheterization with a 12F transseptal sheath. Although the incidence of iasd is high immediately postprocedure, 10% of patients had a residual iasd at 1-year follow-up. In addition, no significant difference in embolic events was observed during the follow-up period in patients with and without a residual iasd. These findings suggest that transseptal catheterization with larger-diameter sheaths is not associated with additional long-term adverse consequence. Further work to assess the safety of very-large-diameter sheaths is prudent.
Patients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationOcclusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationFabien Praz, Andreas Wahl, Sophie Beney, Stephan Windecker, Heinrich P. Mattle*, Bernhard Meier
Procedural Outcome after Percutaneous Closure of Patent Foramen Ovale using the Amplatzer PFO Occluder Without Intra-Procedural Echocardiography in 1,000 Patients Fabien Praz, Andreas Wahl, Sophie Beney,
More informationCase Report Pulmonary Vein Compression After Implantation of a Left Atrial Appendage Occluder: Presentation and Discussion of a Case
194 Case Report Pulmonary Vein Compression After Implantation of a Left Atrial Appendage Occluder: Presentation and Discussion of a Case Maryam Ayati MD, Feifan Ouyang MD, KH Kuck MD Department of cardiology,
More informationAtrial fibrillation (AF), one of the
Hellenic J Cardiol 2013; 54: 408-412 Case Report Left Atrial Appendage Occlusion with the Amplatzer Amulet for Stroke Prevention in Atrial Fibrillation: The First Case in Greece Apostolos Tzikas, Lambros
More informationLeft Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016
Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016 Jesse Jorgensen, MD, FACC Director, Cardiac Cath Lab, Greenville Health System Disclosures
More informationATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE ECHOCARDIOGRAPHY IN INTERVENTIONAL CARDIOLOGY
ATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE Aristides G. Panlilio, MD, FPCP, FPCC,FPSE, FASE Philippine Heart Center Chinese General Hospital and Medical Center
More informationAtrial fibrillation (AF) is a common arrhythmia worldwide
Left Atrial Appendage Closure Under Intracardiac Echocardiographic Guidance: Feasibility and Comparison With Transesophageal Echocardiography Yae Matsuo, MD;* Petr Neuzil, MD, PhD;* Jan Petru, MD; Milan
More informationTHINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
More informationTHINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
More informationThe Clinical Impact of Incomplete Left Atrial Appendage Closure With the Watchman Device in Patients With Atrial Fibrillation
Journal of the American College of Cardiology Vol. 59, No. 10, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.028
More informationAtrial fibrillation (AF) affects approximately 33 million
Emerging Options for Anticoagulation in LAA Closure Managing anticoagulation and antiplatelet therapy in patients undergoing percutaneous left atrial appendage closure with the Watchman device. BY JESSICA
More informationCase Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device
273 Case Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device Amena Hussain MD, Muhamed Saric MD, Scott Bernstein MD, Douglas Holmes MD, Larry Chinitz MD NYU Langone Medical Center, United
More informationTHINK OUTSIDE THE PILLBOX
WATCHMAN : A CLINICALLY PROVEN AND SAFE THERAPY FOR YOUR NVAF PATIENTS WATCHMAN reduces the risk of stroke in NVAF patients as effectively as warfarin WATCHMAN also reduces the long-term risk of bleeding
More informationRahul Jhaveri, M.D. The Heart Group of Lancaster General Health
Rahul Jhaveri, M.D. The Heart Group of Lancaster General Health INTRODUCTION Three recently published randomized controlled trials in The New England Journal of Medicine provide new information about closure
More informationLeft atrial appendage closure with the Amplatzer Cardiac Plug: Rationale for a higher degree of device oversizing at implantation
ORIGINAL ARTICLE Cardiology Journal 2015, Vol. 22, No. 2, 201 205 DOI: 10.5603/CJ.a2014.0063 Copyright 2015 Via Medica ISSN 1897 5593 Left atrial appendage closure with the Amplatzer Cardiac Plug: Rationale
More informationAbstract 1 INTRODUCTION ORIGINAL ARTICLE
Received: 5 October 2017 Revised: 2 November 2017 Accepted: 6 November 2017 DOI: 10.1111/jce.13385 ORIGINAL ARTICLE Feasibility of percutaneous left atrial appendage closure using a novel LAmbre occluder
More informationDevices to Protect Against Stroke in Atrial Fibrillation
Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria
More informationPatent Foramen Ovale: Diagnosis and Treatment
Patent Foramen Ovale: Diagnosis and Treatment Anthony DeMaria Judy and Jack White Chair in Cardiology University of California, San Diego At one time or another a Grantee, Sponsored Speaker or Ad-hoc Consultant
More informationHaemodynamic and functional consequences of the iatrogenic atrial septal defect following Mitraclip therapy
Neth Heart J (2017) 25:137 142 DOI 10.1007/s12471-016-0928-1 REVIEW ARTICLE Haemodynamic and functional consequences of the iatrogenic atrial septal defect following Mitraclip therapy E. A. Hart 1 K.Zwart
More informationDevices for Stroke Prevention. Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP
Devices for Stroke Prevention Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP Overview Left Atrial Appendage Closure FDA Approved Watchman Investigational Amulet PFO Closure Atrial Fibrillation
More informationPREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation
PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation Dr. Saibal Kar, MD TCT 2017 Late Breaking Clinical
More informationCombined catheter ablation and left atrial appendage closure as a. treatment of atrial fibrillation
Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation Giulio Molon, MD FACC, FESC, Fellow ANMCO Card Dept, S.Cuore hospital Negrar
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute ischemic stroke TOAST classification of, 270 Acute myocardial infarction (AMI) cardioembolic stroke following, 207 208 noncardioembolic
More informationLeft Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE
Left Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE Adam Greenbaum, MD NCVH Detroit 2015-09-12 Disclosures Former proctor: SentreHEART Discussion may include the use of non-fda approved devices
More informationRole of cardiac imaging for catheterbased left atrial appendage closure
Role of cardiac imaging for catheterbased left atrial appendage closure Ana G. Almeida, MD, PhD Cardiology University Hospital Santa Maria, Lisbon Ana G. Almeida, MD, PhD, FESC University Hospital Santa
More informationFilling the gap: interventional occlusion of incompletely ligated left atrial appendages
Europace (2015) 17, 64 68 doi:10.1093/europace/euu164 CLINICAL RESEARCH Ablation for atrial fibrillation Filling the gap: interventional occlusion of incompletely ligated left atrial appendages Stefano
More informationDifferent transseptal puncture for different procedures: Optimization of left atrial catheterization guided by transesophageal echocardiography
Original Article Different transseptal puncture for different procedures: Optimization of left atrial catheterization guided by transesophageal echocardiography Andrea Radinovic 1, Patrizio Mazzone 1,
More informationDad needed to get off his blood thinner. His doctor told us about an alternative. It s called
Dad needed to get off his blood thinner. His doctor told us about an alternative. It s called A one-time procedure that may reduce stroke risk for a lifetime in people with AFib not caused by a heart valve
More informationLeft atrial catheter ablation subsequent to Watchman w left atrial appendage device implantation: a single centre experience
Europace (2015) 17, 1402 1406 doi:10.1093/europace/euv037 CLINICAL RESEARCH Ablation for atrial fibrillation Left atrial catheter ablation subsequent to Watchman w left atrial appendage device implantation:
More informationAppendage Closure. Jason Rogers, MD. Director, Interventional Cardiology UC Davis Medical Center Sacramento, California
Appendage Closure Jason Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Sacramento, California Left Atrium: Atrial Fibrillation Left Atrial Appendage Left Atrium Incidence of Atrial
More informationEchocardiographic Guidance During Placement of the Buttoned Double-Disk Device for Atrial Septa1 Defect Closure
Echocardiographic Guidance During Placement of the Buttoned Double-Disk Device for Atrial Septa1 Defect Closure L. LUANN MINICH, M.D., and A. REBECCA SNIDER, M.D. Department of Pediatrics, C.S. Mott Children
More informationWatchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg
Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure
More informationInterventional solutions for atrial fibrillation in patients with heart failure
Interventional solutions for atrial fibrillation in patients with heart failure Advances in Cardiovascular Arrhythmias Great Innovations in Cardiology Matteo Anselmino, MD PhD Division of Cardiology Department
More informationWATCHMAN PROTECT AF Study Rev. 6
WATCHMAN PROTECT AF Study Rev. 6 Protocol Synopsis Title WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) Sponsor Atritech/Boston Scientific
More informationTITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations
TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations DATE: 29 September 2010 CONTEXT AND POLICY ISSUES: Atrial fibrillation (AF) is the irregular, rapid beating of the
More informationPercutaneous Epicardial LAA Closure: When Does it Make Sense?
Percutaneous Epicardial LAA Closure: When Does it Make Sense? Petr Neuzil, MD,PhD, FESC Professor of Medicine Cardiology department Na Homolce Hospital, Prague, Czechia petr.neuzil@gmail.com Disclosures
More informationYES. Your Guide to Getting WATCHMAN. Is a life without blood thinners possible?
Your Guide to Getting WATCHMAN Is a life without blood thinners possible? YES. WATCHMAN is for people with atrial fibrillation not caused by a heart valve problem who need an alternative to warfarin for
More informationTechnique, Risk, and Benefit. T. Santoso University of Indonesia Medical School,
Left Atrial Appendage Closure Technique, Risk, and Benefit T. Santoso University of Indonesia Medical School, Medistra Hospital, Jakarta, Indonesia Percutaneous LAA Closure Devices PLAATO (no longerdeveloped)
More informationStructural Heart Disease: Setting the Stage for Success
Structural Heart Disease: Setting the Stage for Success Brenda McCulloch, RN MSN RCIS Cardiovascular Clinical Nurse Specialist, Interventional & Medical Cardiology Sutter Medical Center, Sacramento mccullb@sutterhealth.org
More informationPatent foramen ovale (PFO) is composed of
PFO Closure for Prevention of Recurrent Cryptogenic Stroke The evidence base is here. BY JOHN F. RHODES, JR, MD Patent foramen ovale (PFO) is composed of overlapping portions of septum primum and septum
More informationPERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE AND ATRIAL SEPTAL DEFECT: STATE OF THE ART AND A CRITICAL APPRAISAL
PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE AND ATRIAL SEPTAL DEFECT: STATE OF THE ART AND A CRITICAL APPRAISAL Carmelo Cernigliaro Clinica San Gaudenzio Novara Eco 2D e 3D Eco Transesofageo Large shunt
More informationWorld Journal of Cardiology. Difficult case of a trans-septal puncture: Use of a SafeSept guidewire
W J C World Journal of Cardiology Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.4330/wjc.v7.i8.499 World J Cardiol 2015 August 26; 7(8): 499-503
More informationContinuing Cardiology Education
Continuing Cardiology Education REVIEW ARTICLE Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: indications diversity and future perspectives A. Tzikas 1 & T.
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationWatchman a Stroke Prevention Technology for Patients with Atrial Fibrillation
Watchman a Stroke Prevention Technology for Patients with Atrial Fibrillation Scripps hospital,la Jolla, CA Atrial fibrillation is a major source of cardiogenic embolic related stroke 500,000 strokes per
More informationEffect of Having a PFO Occlusion Device in Place in the RESPECT PFO Closure Trial
Effect of Having a PFO Occlusion Device in Place in the RESPECT PFO Closure Trial DAVID E. THALER, MD, PHD, JEFFREY L. SAVER, MD RICHARD W. SMALLING, MD, PHD, JOHN D. CARROLL, MD, SCOTT BERRY, PHD, LEE
More informationLeft Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation Zoltan G. Turi, M.D. Rutgers Robert Wood Johnson Medical School New Brunswick, NJ Disclosure Information Zoltan G.
More informationMedical Policy Manual. Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation. Date of Origin: December 2011
Medical Policy Manual Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Date of Origin: December 2011 Section: Medicine Last Reviewed Date: October 2013 Policy No:
More informationRuolo della ablazione della fibrillazione atriale nello scompenso cardiaco
Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco Matteo Anselmino Division of Cardiology Città della Salute e della Scienza Hospital University of Turin, Italy Disclosure: Honoraria
More informationNCVH Birmingham 2013 August 24, Michael S. Bailey, MD Birmingham Heart Clinic
NCVH Birmingham 2013 August 24, 2013 Michael S. Bailey, MD Birmingham Heart Clinic NCVH Birmingham 2015 August 29, 2015 Michael S. Bailey, MD Birmingham Heart Clinic Left Atrial Anatomy Part of a larger
More informationFor Personal Use. Copyright HMP 2013
Case Report J INVASIVE CARDIOL 2013;25(2):E42-E44 Percutaneous Closure of Iatrogenic Ventricular Septal Defect Following Surgical Aortic Valve Replacement Using Two Different Approaches Takashi Matsumoto,
More informationTranscatheter closure of patent foramen ovale using the internal jugular venous approach
New methods in diagnosis and therapy Transcatheter closure of patent foramen ovale using the internal jugular venous approach Przemysław Węglarz 1,2, Ewa Konarska-Kuszewska 2, Tadeusz Zębik 2, Piotr Kuszewski
More informationPatent Foramen Ovale Closure Without Echocardiographic Control: Use of Standby Intracardiac Ultrasound
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 4, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.05.006 Patent Foramen
More informationΕπιπλοκές κατάλυσης πνευµονικών φλεβών
Επιπλοκές κατάλυσης πνευµονικών φλεβών Παναγιώτης Ιωαννίδης Διευθυντής Τµήµατος Αρρυθµιών & Επεµβατικής Ηλεκτροφυσιολογίας Βιοκλινικής Αθηνών ΣΕΜΙΝΑΡΙΑ ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ Ιωάννινα, 27-2-2015 Solving an equation
More informationCryptogenic Stroke: What Don t We Know. Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare
Cryptogenic Stroke: What Don t We Know Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare Financial Disclosures None Objectives Principles of diagnostic evaluation
More informationModern aspects in multidisciplinary thromboembolic prophylaxis. AMPLATZER Left Atrial Appendage data update
Modern aspects in multidisciplinary thromboembolic prophylaxis AMPLATZER Left Atrial Appendage data update Igal Moarof, MD Interventional Cardiology Kantonsspital Aarau Potential conflicts of interest
More informationAtrial fibrillation (AF) is the most common sustained
Safety of Percutaneous Left Atrial Appendage Closure Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access
More informationCryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
More informationLeft Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD
Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD Director of Interventional Cardiac Research Cedars Sinai Medical Center Disclosure Statement
More informationSURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators ACC Late Breaking Clinical Trials March 16,
More informationLeft Atrial Appendage Closure: Techniques and Guidelines. Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA
Left Atrial Appendage Closure: Techniques and Guidelines Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA May is Stroke Awareness Month 2 September is AF Awareness Month Lecture Highlights
More informationKadlec Regional Medical Center Cardiac Electrophysiology WATCHMAN Left Atrial Appendage Closure Device
Patient Information Guide Kadlec Regional Medical Center Cardiac Electrophysiology WATCHMAN Left Atrial Appendage Closure Device Your doctor has recommended that you consider undergoing a procedure to
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationGERIATRICS CASE PRESENTATION
GERIATRICS CASE PRESENTATION CASE 79 year old Patient X was admitted to hospital with SOB. He had a hx of sarcoidosis and asbestosis. Home oxygen requirement is 3-3.5litre. He was admitted, given ceftriaxone
More informationIs there a role for transcatheter left atrial appendage occlusion?
REVIEW Review Is there a role for transcatheter left atrial appendage occlusion? For patients with atrial fibrillation, successful warfarin therapy is difficult in clinical practice. Thus, it seems logical
More informationDiversion of the inferior vena cava following repair of atrial septal defect causing hypoxemia
Marshall University Marshall Digital Scholar Internal Medicine Faculty Research Spring 5-2004 Diversion of the inferior vena cava following repair of atrial septal defect causing hypoxemia Ellen A. Thompson
More informationCLOSE. Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence
CLOSE Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence Guillaume TURC, MD, PhD Paris Descartes University Sainte-Anne hospital Paris, France On
More informationDevice-associated thrombus after percutaneous left atrial appendage closure: a case report and literature review
CSE REPORT Iwona Świątkiewicz, Marek Woźnicki, dam Sukiennik, Jacek Kubica Department of Cardiology and Internal Medicine, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, ydgoszcz, Poland
More informationA PATIENT S GUIDE TO THE LEFT ATRIAL APPENDAGE CLOSURE. Reducing the risk of stroke in atrial fibrillation
A PATIENT S GUIDE TO THE LEFT ATRIAL APPENDAGE CLOSURE Reducing the risk of stroke in atrial fibrillation TABLE OF CONTENTS IMPORTANT Please Note: Information provided by Boston Scientific Corporation
More informationTransseptal catheterization is an established
Site-Specific Transseptal Puncture for Emerging Structural Heart Interventions Imaging-assisted techniques for accurate access. By Michael J. Rinaldi, MD, FACC, FSCAI; Markus Scherer, MD, FACC, FSCCT;
More informationI, (Issam Moussa) DO NOT have a financial interest/arrangement t/ t or affiliation with one or more organizations that could be perceived as a real
PFO Closure: Where We Are Going to after CLOSURE I Study? Issam D. Moussa, MD Professor of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, Florida Disclosure Statement of
More informationRaphael Rosso MD, Yuval Levi Med. Eng., Sami Viskin MD Tel Aviv Sourasky Medical Center
Radiofrequency Ablation of Atrial Fibrillation: Comparison of Success Rate of Circular Ablation vs Point-by-Point Ablation with Contact Force Assessment in Paroxysmal and Persistent Atrial Fibrillation
More informationLAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC
LAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC INTERVENTIONAL CARDIOLOGIST DIRECTOR, ADULT CARDIOLOGY FELLOWSHIP TRAINING
More informationPFO (Patent Foramen Ovale): Smoking Gun or an Innocent Bystander?
PFO (Patent Foramen Ovale): Smoking Gun or an Innocent Bystander? J Thompson Sullebarger, M.D. Florida Cardiovascular Institute University of South Florida Kris Letang Tedy Bruschi Bret Michaels The Atrial
More informationCongenital Absence of the Left Atrial Appendage Visualized by 3D Echocardiography in Two Adult Patients
DOI: 10.1111/echo.12882 2015, Wiley Periodicals, Inc. Echocardiography CASE REPORT Congenital Absence of the Left Atrial Appendage Visualized by 3D Echocardiography in Two Adult Patients Mona Saleh, B.A.,*
More informationUpdate in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
More information[N] = No product variation, policy applies as stated [Y] = Standard product coverage varies from application of this policy, see below
Original Issue Date (Created): July 26, 2011 Most Recent Review Date (Revised): November 26, 2013 Effective Date: February 1, 2014 I. POLICY The use of percutaneous left-atrial appendage closure devices
More informationChapter 76 Left Atrial Appendage Closure: Indication and Technique
Chapter 76 Left Atrial Appendage Closure: Indication and Technique RANJAN SHETTY INTRODUCTION Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, which affects around 3% 5% of the population
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationLeft-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Medical Policy Manual Surgery, Policy No. 195 Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Next Review: November 2019 Last Review: January 2019 Effective: February
More informationWATCHMAN REIMBURSEMENT GUIDE. This comprehensive guide provides an overview of the coding, coverage and payment landscape for the WATCHMAN system.
WATCHMAN REIMBURSEMENT GUIDE This comprehensive guide provides an overview of the coding, coverage and payment landscape for the WATCHMAN system. For questions regarding WATCHMAN reimbursement, please
More informationWhy Treat Patent Forman Ovale
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural Heart Disease Rush University Medical Center Conclusions
More informationListen to Your Heart. What Everyone Needs To Know About Atrial Fibrillation & Stroke. The S-ICD System. The protection you need
Listen to Your Heart The S-ICD System What Everyone Needs To Know About Atrial Fibrillation & Stroke The protection you need without Stroke. touching Are you your at heart risk? Increase your knowledge.
More informationEAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism. Luigi P. Badano, MD, FESC
EAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism Luigi P. Badano, MD, FESC Background Stroke is the 3 cause of death in several industrial countries; Embolism accounts for 15-30%
More informationCommercial Products Percutaneous left atrial appendage closure is considered medically necessary when the criteria above is met.
Medical Coverage Policy Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation EFFECTIVE DATE: 07 01 2016 POLICY LAST UPDATED: 09 04 2018 OVERVIEW Stroke prevention
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationWatchman. Left Atrial Appendage Closure Device. Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8
TM Watchman Left Atrial Appendage Closure Device PROOF OFLEADERSHIP Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8 Patients with AF have a 5x increased risk of stroke.
More informationIndex. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Alagille syndrome, pulmonary artery stenosis in, 143 145, 148 149 Amplatz devices for atrial septal defect closure, 42 46 for coronary
More informationRepair or Replacement
Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationAdded value of transoesophageal echocardiography during transseptal puncture performed by inexperienced operators
Europace (2012) 14, 661 665 doi:10.1093/europace/eur366 CLINICAL RESEARCH Ablation for Atrial Fibrillation Added value of transoesophageal echocardiography during transseptal puncture performed by inexperienced
More informationIntroduction EP WIRE. ... Keywords
Europace (217), 1 6 doi:1.3/europace/eux254 EP WIRE Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association
More informationReview Article Thromboembolism Prevention via Transcatheter Left Atrial Appendage Closure with Transeosophageal Echocardiography Guidance
Hindawi Publishing Corporation rombosis Volume 2014, Article ID 832752, 6 pages http://dx.doi.org/10.1155/2014/832752 Review Article Thromboembolism Prevention via Transcatheter Left Atrial Appendage Closure
More information2017 Cardiovascular Symposium CRYPTOGENIC STROKE: A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A.
CRYPTOGENIC STROKE: 2017 Cardiovascular Symposium A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A. CRYPTOGENIC STROKE CRYPTOGENIC: OF OBSCURE OR UNKNOWN
More informationLeft Atrial Appendage Closure: Neurological events
Left Atrial Appendage Closure: Neurological events Medical Director- Foundation for Cardiovascular Medicine San Diego, CA Director Advanced Interventional Therapies- Gagnon Cardiovascular Institute, Morristown,
More informationNational Imaging Associates, Inc. Clinical guidelines CARDIAC CATHETERIZATION -LEFT HEART CATHETERIZATION. Original Date: October 2015 Page 1 of 5
National Imaging Associates, Inc. Clinical guidelines CARDIAC CATHETERIZATION -LEFT HEART CATHETERIZATION CPT Codes: 93451, 93452, 93453, 93454, 93455, 93456, 93457, 93458, 93459, 93460, 93461 LCD ID Number:
More informationPercutaneous closure of a patent foramen ovale after cryptogenic stroke
Neth Heart J (2018) 26:5 12 https://doi.org/10.1007/s12471-017-1063-3 POINT OF VIEW Percutaneous closure of a patent foramen ovale after cryptogenic stroke R. J. R. Snijder 1 M.J.Suttorp 1 J.M.tenBerg
More informationSHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY
SHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY SHARED DECISION MAKING: AN EVIDENCE BASED CORNERSTONE OF LAAC THERAPY Shared decision making is a collaborative process that allows
More informationOrganic mitral regurgitation
The best in heart valve disease Organic mitral regurgitation Ewa Szymczyk Department of Cardiology Medical University of Lodz, Poland I have nothing to declare Organic mitral regurgitation leaflet abnormality
More information